John David Diekman
Lead Independent DirectorDr. John David Diekman, Ph.D., serves as Lead Independent Director at Zai Lab Limited since July 2022. He serves as a Director at Cleave Therapeutics, Inc. He has been the Founding Partner at 5AM Venture Management LLC since January 2016. Dr. Diekman serves as an Advisor at Bio*One Capital Pte Ltd. Dr. Diekman founded 5AM in 2002 and served as its Managing Partner from 2002 to 2015. He has been Managing Partner of 5AM Ventures IV, L.P., since 2002. He is employed at Venture Associates AG. He serves as an Advisor of Clearbridge Accelerator. He served as Consultant of Aravis SA. He served as the Chief Executive Officer and Managing Director of Affymetrix, Inc. Dr. Diekman served as an Advisor of EDB Investments Pte. Ltd. and was contributing on a part-time basis since 2002. He founded Bay City Capital LLC and served as its Managing Director, where he was primarily involved in the investment activities of BCC Fund I. He managed and led several biotechnology companies ranging from early product development to established public companies. Prior to such time, he served as the President and Chief Operating Officer of Affymax N.V. (Affymax) from 1991 to March 1995 and as the Chairman and Managing Director of the Affymax Board since 1994. He served as the President of Monoclonal Antibodies Inc. and the President of Salutar. He served as the President and Chief Executive Officer of Zoecon Corporation. He serves as Chairman at 5AM Venture Management LLC., & 5AM Ventures, L.P. He served as an Independent Chairman of IDEAYA Biosciences, Inc. until June 16, 2020 and served as its Independent Director since May 2016 until June 16, 2020. He serves as Vice Chairman of Bay City Capital. He serves as Chairman of Scripps Research Institute. Dr. Diekman serves as Chairman of Molecular Applications Group, California Institute for Biomedical Research and Envoy Therapeutics, Inc. He serves as Director at Takeda California, Inc., Panomics, Inc., Qiagen Redwood City, Inc., Igenica Biotherapeutics, Inc., Hill Top Research, Genospectra Inc., The Tech Museum of Innovation, Aravis Venture I and Syrrx. Dr. Diekman serves as a Director of Wildcat Discovery Technologies, Inc. and served as its Board Observer. He served as a Board Observer of IDEAYA Biosciences, Inc. He also serves on the Schaeffer Center for Health Policy and Economics Advisory Board at the University of Southern California. He serves as a Board Member at Cellular Research, Inc. Previoulsy, Dr. Diekman served as a Member of Scientific Advisory Board of Biotechnology Turnaround Fund B.V. He is a Charter Trustee of Princeton University. Dr. Diekman serves as an Honorary Officer in the Order of Australia. He is a Special Advisor to the Singapore Economic Development Board. He is also former Trustee of The California Institute of Technology where he served as the Chairman and The Scripps Research Institute. He served as the Chairman of the Board of Ambrx, Inc. since August 2003. Dr. Diekman served as the Chairman of Phenomix Corporation. He served as Chairman at Affymetrix, Inc. He served as Vice Chairman of Bio*One Capital Pte Ltd. He served as a Director of Kalypsys, Inc., Metabolex, Inc. and Quidel Corp. He served as a Board Director of Chemdex, Wildcat Discovery Technologies, Inc, Envoy, Ingenuity Systems, Inc and LJL BioSystems Inc. Dr. Diekman served as a Director of Phenomix Corporation since February 2002. He served as a Director of Cymabay Therapeutics, Inc. Dr. Diekman serves on the Board of the California Institute of Technology. He has been an Independent Director of ZAI Lab Limited since 2017. He served as a Director of S*BIO Pte Ltd. and Affymetrix, Inc. from 1993 to May 7, 2013. He served as a Director of PhaseRx, Inc., Antipodean Pharmaceuticals Inc. and Marcadia Biotech, Inc. He served as Board of Director at Calibrium. He has experience in the life science industry. Dr. Diekman holds an Honorary Doctor of Laws Degree from Monash University. He holds a Ph.D. in Chemistry from Stanford University and a B.A. degree in Chemistry from Princeton University.
Positions
- Company NameZai Lab LimitedStock Code09688PositionLead Independent DirectorRelated SecuritiesColleagues
- YDYing DuFounder, Chairperson & CEO
- RGRafael G. AmadoPresident and Head of Global Research & Development
- YCYajing ChenChief Financial Officer
- FTFrazor Titus EdmondsonChief Legal Officer & Corporate Secretary
- CCChristine ChiouSenior VP & Head of Investor Relations
- PKPeter Karl WirthIndependent Director
- SWScott William MorrisonIndependent Director
- WDWilliam David LisIndependent Director
